Cite

HARVARD Citation

    Mathew Thomas, V. et al. (2020). Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. Journal of oncology pharmacy practice. pp. 459-461. [Online]. 
  
Back to record